October 2, 2020 Comments Off on Ocera Therapeutics Inc. Investment Losses Blog, Current Investigations

Ocera Therapeutics Inc. Investment Losses

Ocera Therapeutics Inc. Investment Losses, featured by top securities fraud attorneys, The White Law Group

Concerned about your investment in Ocera Therapeutics Inc.? 

Are you concerned about your investment losses in Ocera Therapeutics Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Ocera Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need, according to Bloomberg. 

In December 2017, generic drug manufacturer Mallinckrodt merged its subsidiary with and into Ocera without a vote of Ocera’s other stockholders, according to a press announcement. As a result of the completed merger, Ocera became an indirect, wholly owned subsidiary of Mallinckrodt. 

All Ocera shares not validly tendered into a tender offer were reportedly cancelled and converted into the right to receive $1.52 per share, plus one Contingent Value Right to receive one or more payments in cash of up to $2.58 per share, which is the same price per share offered in the tender offer. As a result of the acquisition, Ocera shares reportedly halted trading on NASDAQ, according to the announcement.

Ocera Therapeutics Inc. filed a form D to raise capital from investors in 2017, according to filings with the SEC. The total offering amount sold was purportedly $28,000,000.

Filing a Complaint against your Brokerage Firm 

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with pharmaceutical and biotech investments such as Ocera Therapeutics Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Ocera Therapeutics Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

Comments are closed.